%PDF-1.4
%
54 0 obj
<>
endobj
51 0 obj
<>
endobj
134 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-06T19:44:54Z
2024-03-29T00:43:52-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-29T00:43:52-07:00
application/pdf
Heather
2003-33.nov
uuid:a804bce8-1dd1-11b2-0a00-770927bd7200
uuid:a804bcea-1dd1-11b2-0a00-880000000000
endstream
endobj
40 0 obj
<>
endobj
41 0 obj
<>
endobj
55 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 24 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 26 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 28 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 30 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
159 0 obj
[163 0 R]
endobj
160 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 61 714.5293 Tm
[(2.)-875.1 (Okano )36.8 (Y)128.9 (.)-0.1 ( )54.8 (Antinuclear antibody in systemic sclerosis \(scleroderma\).)]TJ
1.675 -1.25 Td
[(Rheum Dis Clin North )54.8 (Am 1996;22:709-35.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Kuwana M, Kaburaki J, Mimori )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (ojo )17.7 (T)74 (, Homma M.)]TJ
1.675 -1.25 Td
[(Autoantibody reactive with three classes of RNA)-220.2 (polymerases in)]TJ
0 -1.25 TD
(sera from patients with systemic sclerosis. J Clin Invest)Tj
0 Tc 0 Tw T*
(1993;91:1399-404.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Okano )36.8 (Y)128.9 (, Steen )17.7 (VD, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)54.8 (. )54.8 (Autoantibody reactive with)]TJ
1.675 -1.25 Td
[(RNA)-220.2 (polymerase III in systemic sclerosis. )54.8 (Ann Intern Med)]TJ
0 Tc 0 Tw T*
[(1993;1)36.9 (19:1005-13.)]TJ
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Satoh M, )54.8 (Ajmani )54.8 (AK, Ogasawara )17.7 (T)74 (, et al. )54.8 (Autoantibodies to RNA)]TJ
1.675 -1.25 Td
(polymerase II are common in systemic lupus erythematosus and)Tj
T*
(overlap syndrome. J Clin Invest 1994;94:1981-9.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Kuwana M, Okano )36.8 (Y)128.9 (, Kaburaki J, )17.7 (T)69.9 (ojo )17.7 (T)74 (, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)54.8 (. Racial)]TJ
1.675 -1.25 Td
[(dif)17.7 (ferences in the distribution of systemic sclerosis-related serum)]TJ
T*
[(antinuclear antibodies. )54.8 (Arthritis Rheum 1994;37:902-6.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Mayes MD. Scleroderma epidemiology)64.8 (. Rheum Dis Clin North )54.8 (Am)]TJ
0 Tc 0 Tw 1.675 -1.25 Td
(1996;22:751-64.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Whiteside )17.7 (TL, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, Rodnan GP)110.8 (. HLA-DR antigens in)]TJ
1.675 -1.25 Td
(progressive systemic sclerosis \(scleroderma\). J Rheumatol)Tj
0 Tc 0 Tw T*
(1983;10:128-31.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Livingston JZ, Scott )17.7 (TE, )17.7 (W)39.8 (igley FM, et al. Systemic sclerosis )]TJ
1.675 -1.25 Td
(\(scleroderma\): clinical, genetic and serologic subsets. J Rheumatol)Tj
0 Tc 0 Tw T*
(1987;14:512-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (Luderschmidt C, Scholz S, Mehlhaf)17.7 (f E, Konig G, )54.8 (Albert E.)]TJ
2.175 -1.25 Td
(Association of progressive systemic scleroderma to several HLA-B)Tj
T*
[(and HLA-DR alleles. )54.8 (Arch Dermatol 1987;123:1)36.8 (188-91.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Arnett FC. HLA)-220.2 (and autoimmunity in scleroderma \(systemic )]TJ
2.1381 -1.25 Td
(sclerosis\). Int Rev Immunol 1995;12:107-28.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Kuwana M, Inoko H, Kameda H, et al. )54.8 (Association of human)]TJ
2.175 -1.25 Td
(leukocyte antigen class II genes with autoantibody profiles, but not)Tj
T*
(with disease susceptibility in Japanese patients with systemic )Tj
T*
(sclerosis. Intern Med 1999;38:336-44.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Reveille JD, Durban E, MacLeod-St. Clair MJ, et al. )54.8 (Association of)]TJ
2.175 -1.25 Td
(amino acid sequences in the HLA-DQB1 first domain with the )Tj
T*
(antitopoisomerase I autoantibody response in scleroderma )Tj
T*
(\(progressive systemic sclerosis\). J Clin Invest 1992;90:973-80.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Kuwana M, Kaburaki J, Okano )36.8 (Y)128.9 (,)-0.1 ( Inoko H, )17.7 (T)69.9 (suji K. )17.7 (The HLA-DR)]TJ
2.175 -1.25 Td
(and DQ genes control the autoimmune response to DNA)Tj
T*
(topoisomerase I in systemic sclerosis \(scleroderma\). J Clin Invest)Tj
0 Tc 0 Tw T*
(1993;92:1296-301.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(15.)-875.1 (Morel P)91.7 (A, Chang HJ, )17.7 (W)39.8 (ilson JW)91.7 (, et al. Severe systemic sclerosis)]TJ
2.175 -1.25 Td
(with anti-topoisomerase I antibodies is associated with an )Tj
T*
[(HLA-DRw1)36.8 (1 allele. Hum Immunol 1994;40:101-10.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Reveille JD, Owerbach D, Goldstein R, Moreda R, Isern RA, )54.8 (Arnett)]TJ
2.175 -1.25 Td
[(FC. )54.8 (Association of polar amino acids at position 26 of the )]TJ
T*
(HLA-DQB1 first domain with the anticentromere autoantibody)Tj
T*
(response in systemic sclerosis \(scleroderma\). J Clin Invest)Tj
0 Tc 0 Tw T*
(1992;89:1208-13.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Kuwana M, Okano )36.8 (Y)128.9 (, Kaburaki J, Inoko H. HLA)-220.2 (class II genes)]TJ
2.175 -1.25 Td
(associated with anticentromere antibody in Japanese patients with)Tj
T*
[(systemic sclerosis \(scleroderma\). )54.8 (Ann Rhuem Dis 1995;54:983-7.)]TJ
-2.175 -1.25 Td
[(18.)-875.1 (Kuwana M, Okano )36.8 (Y)128.9 (, Kaburaki J, )17.7 (T)69.9 (suji K, Inoko H. MHC class II)]TJ
2.175 -1.25 Td
(associations with anti-U1 small nuclear ribonucleoprotein antibody:)Tj
T*
(relationship to immunoreactivity with individual constituent)Tj
T*
[(proteins. )54.8 (Arthritis Rheum 1995;38:396-405.)]TJ
-2.175 -1.25 Td
[(19.)-875.1 (Arnett FC, Reveille JD, Goldstein R, et al. )54.8 (Autoantibodies to )]TJ
2.175 -1.25 Td
(fibrillarin in systemic sclerosis \(scleroderma\): an immunogenetic,)Tj
T*
[(serologic, and clinical analysis. )54.8 (Arthritis Rheum 1996;39:1)36.8 (151-60.)]TJ
-2.175 -1.25 Td
[(20.)-875.1 (Falkner D, )17.7 (W)39.9 (ilson J, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, Morel P)91.7 (A. HLA)-220.2 (and clinical)]TJ
2.175 -1.25 Td
[(associations in systemic sclerosis patients with anti-Th/T)69.7 (o )]TJ
T*
[(antibodies. )54.8 (Arthritis Rheum 1998;41:74-80.)]TJ
0 Tc -2.175 -1.25 Td
[(21.)-875 (Oddis CV)128.9 (, Okano )36.8 (Y)129 (,)0.1 ( Rudert )17.7 (W)111 (A, )17.7 (T)35.1 (rucco M, Duquesnoy RJ,)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(Medsger )17.7 (T)79.9 (A)-220.1 (Jr)54.8 (. Serum autoantibody to the nucleolar antigen )]TJ
T*
[(PM-Scl: clinical and immunogenetic associations. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
[(1992;35:121)36.9 (1-7.)]TJ
-0.00011 Tc 0.02499 Tw 30.825 80 Td
[(22.)-875.1 (Kuwana M, Kaburaki J, )54.8 (Arnett FC, Howard RF)79.7 (, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (,)]TJ
2.175 -1.25 Td
[(W)39.8 (right )17.7 (TM. Influence of ethnic background on clinical and )]TJ
T*
(serologic features in patients with systemic sclerosis and anti-DNA)Tj
T*
[(topoisomerase I antibody)64.8 (. )54.8 (Arthritis Rheum 1999;42:465-74.)]TJ
-2.175 -1.25 Td
[(23.)-875.1 (Kuwana M, Kimura K, Hirakata M, Kawakami )36.8 (Y)128.9 (, Ikeda )36.8 (Y)128.9 (.)]TJ
2.175 -1.25 Td
[(Dif)17.7 (ferences in anti-Th/T)69.7 (o autoantibody response between systemic)]TJ
T*
[(sclerosis and other autoimmune diseases. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(2002;61:842-6.)Tj
0.0249 Tw -2.175 -1.25 Td
[(24.)-875 (Fanning GC, )17.7 (W)80 (elsh KI, Bunn C, du Bois R, Black CM. HLA)]TJ
-0.00011 Tc 2.175 -1.25 Td
(associations in three mutually exclusive autoantibody subgroups in)Tj
T*
(UK systemic sclerosis patients. Br J Rheumatol 1998;37:201-7.)Tj
-2.175 -1.25 Td
[(25.)-875.1 (Falkner D, )17.7 (W)39.9 (ilson J, Fertig N, Clawson K, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, Morel)]TJ
2.175 -1.25 Td
[(P)91.8 (A. Studies of HLA-DR and DQ alleles in systemic sclerosis)]TJ
T*
[(patients with autoantibodies to RNA)-220.2 (polymerases and U3-RNA)]TJ
T*
[(\(fibrillarin\). J Rheumatol 2000;27:1)36.8 (196-202.)]TJ
-2.175 -1.25 Td
[(26.)-875.1 (Kuwana M, Okano )36.8 (Y)128.9 (, Kaburaki J, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, )17.7 (W)39.8 (right )17.7 (TM.)]TJ
2.175 -1.25 Td
[(Autoantibodies to RNA)-220.2 (polymerases recognize multiple subunits)]TJ
T*
[(and demonstrate cross-reactivity with RNA)-220.2 (polymerase complexes.)]TJ
T*
(Arthritis Rheum 1999;42:275-84.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Masi )54.8 (A)110.8 (T)74 (, Rodnan GP)110.7 (, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, et al. Preliminary criteria for)]TJ
2.175 -1.25 Td
[(the classification of systemic sclerosis \(scleroderma\). )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1980;23:581-90.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(28.)-875.1 (Kuwana M, Kaburaki J, Okano )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (ojo )17.7 (T)74 (, Homma M. Clinical and)]TJ
2.175 -1.25 Td
(prognostic associations based on serum antinuclear antibodies in)Tj
T*
[(Japanese patients with systemic sclerosis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1994;37:75-83.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(29.)-875.1 (Inoko H, Ota M. PCR-RFLP)110.7 (. In: Hui KM, Bidwell JL, editors.)]TJ
2.175 -1.25 Td
[(Handbook of HLA)-220.2 (typing techniques. Boca Raton: CRC Press;)]TJ
0 Tc 0 Tw T*
(1993:9-70.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(30.)-875.1 (Bunce M, O\325Neill CM, Barnardo MCNM, et al. Phototyping:)]TJ
2.175 -1.25 Td
[(comprehensive DNA)-220.2 (typing for HLA-A, B, C, DRB1, DRB3,)]TJ
T*
(DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing)Tj
T*
[(sequence-specific primers \(PCR-SSP\). )17.7 (T)35 (issue )54.8 (Antigens)]TJ
0 Tc 0 Tw T*
(1995;46:355-67.)Tj
-0.00011 Tc 0.00729 Tw -2.175 -1.25 Td
[(31.)-875.1 (Imanishi T)74 (,)-0.1 ( )37.1 (Akaza T)74 (, )-17.7 (Kimura )37.1 (A, T)69.9 (okunaga )-17.7 (K, )-17.7 (Gojobori T)74 (.)-0.1 ( )37.1 (Allele)]TJ
0.02499 Tw 2.175 -1.25 Td
[(and haplotype frequencies for HLA)-220.2 (and complement loci in various)]TJ
T*
[(ethnic groups. In: )17.7 (T)69.9 (suji K, )54.8 (Aizawa M, Sasazuki )17.7 (T)74 (, editors. HLA)]TJ
T*
(1991. Oxford: Oxford University Press; 1992:1064-223.)Tj
-2.175 -1.25 Td
[(32.)-875.1 (Seither P)110.7 (,)-0.1 ( Coy JF)79.7 (, Pouska )54.8 (A, Grummt I. Molecular cloning and)]TJ
2.175 -1.25 Td
[(characterization of the cDNA)-220.2 (encoding the lar)17.7 (gest subunit of mouse)]TJ
T*
[(RNA)-220.2 (polymerase I. Mol Gen Genet 1997;255:180-6.)]TJ
-2.175 -1.25 Td
[(33.)-875.1 (Stern LJ, Brown JH, Jardetzky )17.7 (TS, et al. Crystal structure of the)]TJ
2.175 -1.25 Td
(human class II MHC protein HLA-DR1 complexed with an)Tj
T*
(influenza virus peptide. Nature 1994;368:215-21.)Tj
0.00729 Tw -2.175 -1.25 Td
[(34.)-875.1 (Kuwana )-17.7 (M, )-17.7 (Medsger T)79.9 (A)-220.1 (Jr)39.7 (, W)39.9 (right TM. T)-257.1 (cell )-17.7 (proliferative)]TJ
0.02499 Tw 2.175 -1.25 Td
[(response induced by DNA)-220.2 (topoisomerase I in patients with)]TJ
T*
(systemic sclerosis and healthy donors. J Clin Invest )Tj
0 Tc 0 Tw T*
(1995;96:586-96.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(35.)-875.1 (Rands )54.8 (AL, )17.7 (Whyte J, Cox B, Hall ND, McHugh NJ. MHC class II)]TJ
2.175 -1.25 Td
[(associations with autoantibody and )17.7 (T)-257.1 (cell immune responses to the)]TJ
T*
[(scleroderma autoantigen topoisomerase I. J )54.8 (Autoimmun)]TJ
0 Tc 0 Tw T*
(2000;15:451-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(36.)-875.1 (Kuwana M, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, )17.7 (W)39.9 (right )17.7 (TM. )17.7 (T)-257.1 (and B cell collaboration)]TJ
2.175 -1.25 Td
[(is essential for the autoantibody response to DNA)-220.2 (topoisomerase I)]TJ
T*
(in systemic sclerosis. J Immunol 1995;155:2703-14.)Tj
-2.175 -1.25 Td
[(37.)-875.1 (Kuwana M, Medsger )17.7 (T)79.9 (A)-220.1 (Jr)39.7 (, )17.7 (W)39.9 (right )17.7 (TM. )54.8 (Analysis of soluble and)]TJ
2.175 -1.25 Td
[(cell surface factors regulating anti-DNA)-220.2 (topoisomerase I )]TJ
T*
[(autoantibody production demonstrates syner)17.7 (gy between )17.7 (Th1 and)]TJ
T*
(Th2 autoreactive cells. J Immunol 2000;164:6138-46.)Tj
ET
0 0 0 0 k
420 777 137 -27 re
f*
408 770 150 -25 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Kuwana, et al: HLA)-257.3 (and anti-RNA)-257.3 (polymerase I/IIII)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(2397)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.09 396.48 -10.84 re
f*
0.5 w
109.22 59.09 396.48 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_2 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
34 0 obj
<>stream
8;Z\6$'+%2#iu"-j?'C[G9->7,I&V".I9+#-CBO^.%L+@YPhfD&_j_Lrd<>p#ku3V
YKJ1nb-/?ULC?>ZrPR5(9#kg5/Ya4Ya!MI+*8:ffGu5Ou:LHith/9=Oi9$`KIesDo
C_l7`irE0s,CnM+)6K57:NQWOT'LR=XGbVeoI;Hm,GZ]4m@?o,7n$n\KK-YrWc"5G
Ri'#i;pZO*kHN9URdaj/4h;D%\Bq7O5*3tc1[:>9e1=TPZHGD4geuY:2BFUaH
h4pkGP7hA9N1;ruQ_:QDHW?Hs`/1Rk2<)@AY_\:g@\FG:H`g-_e^d'knOWh237UlP
d9OsDJN"#nSf=IV0S!UJ:].m_dX%3N-;LQ+\]lAqZXo2iD)YBAQVZ(DX@
;k9r^2".c7WU_E44KqCUC:M?a0%l["pe^bWr2._F2JiGZ3S(o#Fqq09Bu*+KOa?tn
f1i!H?jPUbdmdV70M1Ipm+t-CgqVi8t`;_a:5o
b6)Fa)EVZ=hC4g4H?qR.1[9nee=mStBs)ABdo];5:'2V&<=n/$G45O=b9iD3LE3ms
f:KnNpID;uNbQi3I3S"O!e,X2e1\Wl>GJ(.XJ\_SB<1peUhFM*HMi:sb_sY%'9TnBnj4WAp9P<+Hb>SV%0Tr[p
ggGuX/liBZ(K\r5n9@4$&'+L/>3eCX3"%2)QY!0ff's'<=48;+R8GqCd;HB7?AYPm
j3_2UY%2$(jO<=B:?mikY1kNo%O0b0>uK8uZm*g\r3bkaDZIY5MZa~>
endstream
endobj
38 0 obj
[/Indexed/DeviceRGB 255 37 0 R]
endobj
37 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
67 0 obj
<>
endobj
63 0 obj
<>
endobj
93 0 obj
<>
endobj
140 0 obj
<>
endobj
57 0 obj
<>
endobj
86 0 obj
<>stream
HUiPSY~A1=
qR#*-hk(8M#H !%$AY(AT
]ơqj\mfzjK_zΟ?S[N.`8ܵuy@ȗƧ
oa<0g0^3k2&fqv6!/_HV`gSIgqvM멳>>y>>[E2 )YJ/;1z'+ޡ{\O$>DJ萴"qH/'h: 5~+| _e;HxZ*OŇi!:T&t6:>-qHL} Q/%c59sX,l5cK6aaX
~Ά9C,#"mSll#Y!{vz~#썳gͺ1{cklS<NOv;Ҏ#NNCZ'Ig(>rފyC7qgsc/6
'9-4q9Sg^vbYIO.UR$[+U%y#:
e.N(1l6LH)leY
# ݲBi,HB݄7?pIEnP}eEuƙ꯶~=u;&pJlʦƮe$9eDPg
.j/Bޒ҉,Z?U^(@R.Wvkȿ'Dł92fiMZXR]л
mzzu˄yT61tQA*(h&K:|a6p`xMԌ)EPX!|j#y,`3$
P&nsf&$Xxҳ+mxZ۶UnE"eQI>WۣTj |A7B6Slb<π 7$ahWثo21n(Xk:t&%σ+OWV#+O@l rXlF24
Ʃ#~j|⮬}Jmgs\&*g#ZP"ۚ
kb\-$\{{ƕ]f+,̌m8~SI|ҫlaɝW꧓dz.uC
]'&O]MKh%1ɾ5w^yN^j>Q{DE|Q{H
@7ONi>E8`?TH`_OX9Z/>倁=S_6PaUS69>(^\&P)J ĉAt[حi8Y?pfIT^
+V?wEHoehͮs υPOsMEkRC
*Ёh1pUF ulج4[ /6)G~#CSߥ~@ 1v]VETHDITKsYuq6tp
8d"g/5c+F&H:B
vѢFOB&-!]JfR@H=nu
BNe̮}XF3vYzJn;
\ewȎKs)B<6P:SNӤ-
+E6jn~3Oj\3wvYa790=x4s@X->Ti&Pc\YeDd>-«<3Ke*jSGqkiQZXARdfC $Ba7(J,JUa8zx[[[f}~@@|fptBޔk&˽C<'wwJ/a9p7ܾW32IN#bN4+G
68-\a),%}+ݼgQo?\_Q[wa:lǛМUEzU_wF8TrH!a
r&km@&8C%qqAk f*9H"KtXi5wNp\$OŏTE?h@0֔SdOAxmn)Nhjd`/!\A̙+ ō
wVl*+xC6$,"DbCTUV;$/Kt! g+9cNl+I3_gxR3C](>XܫdY\]-4'E3]#䢚RCnW|
.<_.;l+`l8Kᗊ/e8AqE[)[hw9@yPvWB1[6Gk
+k bNmS(K6nZ=Go?,HvG|NڢeZwzfC=k8}ɡ_5*:)vK`m' p>sy};u5y2=NWtC|